Literature DB >> 11763340

Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies.

P Minor1.   

Abstract

Individuals who are deficient in humoral immunity are particularly at risk from infection with enteroviruses, and poliovirus in particular, where antibodies are the main source of protection from disease. Long-term excretion of vaccine strains of poliovirus has been documented for many years and instances of paralytic poliomyelitis in hypogammaglobulinaemic patients who were subsequently found to have been excreting virus for prolonged periods have been reported in the U.S.A., Germany and Japan. The identification of a healthy immunodeficient patient in the U.K. who has probably been excreting type 2 poliovirus for 15 years will be described, with the characteristics of the virus and the results of attempts at treatment so far. Such individuals pose a significant risk to the eradication programme unless they can be identified and treated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11763340

Source DB:  PubMed          Journal:  Dev Biol (Basel)        ISSN: 1424-6074


  5 in total

1.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 2.  Clearing Vaccine-Derived Poliovirus Infection Following Hematopoietic Stem Cell Transplantation: a Case Report and Review of Literature.

Authors:  Mohammadreza Shaghaghi; Mona Irannejad; Hassan Abolhassani; Shohreh Shahmahmoodi; Amir Ali Hamidieh; Saeed Soleyman-Jahi; Reza Yazdani; Gholamreza Azizi; Asghar Aghamohammadi
Journal:  J Clin Immunol       Date:  2018-06-14       Impact factor: 8.317

3.  Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.

Authors:  Zhaochun Chen; Konstantin Chumakov; Eugenia Dragunsky; Diana Kouiavskaia; Michelle Makiya; Alexander Neverov; Gennady Rezapkin; Andrew Sebrell; Robert Purcell
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

4.  A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses.

Authors:  Diana Kouiavskaia; Zhaochun Chen; Eugenia Dragunsky; Olga Mirochnitchenko; Robert Purcell; Konstantin Chumakov
Journal:  J Clin Virol       Date:  2015-02-03       Impact factor: 3.168

5.  A novel gamma radiation-inactivated sabin-based polio vaccine.

Authors:  Gregory J Tobin; John K Tobin; Elena K Gaidamakova; Taralyn J Wiggins; Ruth V Bushnell; Wai-Ming Lee; Vera Y Matrosova; Stephen J Dollery; Heather N Meeks; Diana Kouiavskaia; Konstantin Chumakov; Michael J Daly
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.